Why oGVHD Is More Than Dry Eye
Ocular graft-versus-host disease, often abbreviated as oGVHD, is sometimes described as a severe form of dry eye. That shorthand is understandable, but it is incomplete.
Dry eye is one of the most visible ways oGVHD is experienced by patients. Burning, grittiness, dryness, light sensitivity, foreign body sensation, tearing, and fluctuating vision are common complaints. But oGVHD is not simply a tear-volume problem. It is an immune-mediated ocular surface disease that can occur after allogeneic hematopoietic stem cell transplantation, when donor-derived immune cells contribute to inflammation and tissue injury in the recipient.
The distinction matters. In routine dry eye disease, the problem may involve tear-film instability, evaporative loss, inflammation, meibomian gland dysfunction, environmental exposure, medication effects, or neurosensory abnormalities. In oGVHD, these same ocular surface features can appear in the setting of transplant-related immune disease. The eye is not merely dry. It may be one target organ in chronic graft-versus-host disease.
In oGVHD, the immune process can affect the lacrimal glands, conjunctiva, cornea, eyelids, meibomian glands, and ocular surface nerves. The lacrimal glands may become inflamed or fibrotic, reducing tear support. The conjunctiva may become inflamed or scarred. Goblet cell function may be impaired, reducing mucin support for the tear film. The corneal epithelium may become fragile. Eyelid and meibomian gland disease may add evaporative stress.
This explains why the patient experience can be severe. The ocular surface is not just a passive covering. It is a living barrier, a sensory structure, and an optical interface. When it breaks down, patients may have difficulty reading, working at a computer, driving, tolerating light, sleeping comfortably, or keeping the eyes open.
oGVHD is also common enough after transplant that it should be part of survivorship education. Published reviews report that ocular GVHD develops in a substantial portion of patients after allogeneic stem cell transplantation, with reported ranges varying by population and diagnostic criteria. One review describes oGVHD developing in approximately 40 to 60 percent of patients following allogeneic stem cell transplantation. A more recent review notes reported chronic oGVHD occurrence of 30 to 60 percent after hematopoietic cell transplantation, and 60 to 90 percent among patients with systemic GVHD.
These ranges should not be read as a single universal rate. They show that oGVHD is a major clinical issue, but diagnosis, population, transplant type, follow-up time, and study methods all affect reported incidence.
For patients and advocates, the practical point is direct: persistent eye symptoms after transplant should not be dismissed as ordinary dryness. For clinicians and researchers, the challenge is to understand oGVHD as an immune-mediated disease of the ocular surface, not simply as dry eye with a transplant history.
That framing matters because treatment goals are broader than comfort alone. The field must also think about inflammation, tissue damage, fibrosis, ocular surface protection, function, quality of life, and long-term vision risk.
This article is for educational purposes only and is not medical advice.
Sources:
Nassiri N, Eslani M, Panahi N, et al. “Ocular Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation.” Journal of Ophthalmic & Vision Research, 2013.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3957042/
Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full
